Completed PHASE1 INTERVENTIONAL 3-arm NCT02811016

Inhaled Budesonide and Acute Mountain Sickness

Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m

Sponsor: Salzburger Landeskliniken

Interventions Budesonide 200 Budesonide 800 Placebo

Updated 5 times since 2017 Last updated: Oct 13, 2016 Started: Jun 30, 2016 Primary completion: Jul 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Mountain Sickness, this trial is completed. The trial is conducted by Salzburger Landeskliniken and has accumulated 5 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Salzburger Landeskliniken
University Hospital Heidelberg

Data source: Salzburger Landeskliniken

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salzburg, Austria